Attach to Form 990 or Form 990-EZ.
See separate instructions.| (i) Name of supported organization |
(ii) EIN |
(iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) |
(iv) Is the organization in col. (i) listed in your governing document? |
(v) Did you notify the organization in col. (i) of your support? |
(vi) Is the organization in col. (i) organized in the U.S.? |
(vii) Amount of support? |
|||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3.. | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public Support. Subtract line 5 from line 4. | ||||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets.. | ||||||
| 11 | Total support (Add lines 7 through 10). | ||||||






| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public Support (Subtract line 7c from line 6.) | ||||||
| Calendar year (or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) | ||||||
| 13 | Total support (Add lines 9, 10c, 11 and 12.). | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| FORM 990, PART VI, SECTION A, LINE 2 | VARI AND VAEI SHARE COMMON MANAGEMENT. AS OFFICERS OF VARI, DAVID VAN ANDEL, R. JACK FRICK, TIMOTHY MYERS AND DAVID WHITESCARVER INTERACT AND WORK TOGETHER WITH STEVE TRIEZENBERG, A KEY EMPLOYEE OF VAEI. | |
| FORM 990, PART VI, SECTION A, LINE 3 | JERRY CALLAHAN, AN INDEPENDENT CONTRACTOR, SERVES AS THE VICE PRESIDENT OF BUSINESS DEVELOPMENT, TECHNOLOGY TRANSFER, AND OFFICE OF GRANTS AND CONTRACTS. | |
| FORM 990, PART VI, SECTION A, LINE 7A | THE TRUSTEES OF VAN ANDEL INSTITUTE HAVE THE AUTHORITY TO ELECT ONE OR MORE MEMBERS OF VARI'S GOVERNING BODY. | |
| FORM 990, PART VI, SECTION B, LINE 11 | FOLLOWING COMPLETION OF THE FINANCIAL AUDIT, THE FORM 990 IS PREPARED AND REVIEWED BY MANAGEMENT. IT IS THEN CIRCULATED TO THE FULL BOARD FOR REVIEW AND FINAL APPROVAL PRIOR TO FILING WITH THE IRS. | |
| FORM 990, PART VI, SECTION B, LINE 12 | VARI HAS A WRITTEN CONFLICT OF INTEREST POLICY FOR WHICH THE ORGANIZATION ENFORCES A PROCESS TO IDENTIFY, EVALUATE, AND CORRECT OR REMOVE POTENTIAL CONFLICTS OF INTEREST. THE VAN ANDEL INSTITUTE ADMINISTERS THE CONFLICT OF INTEREST (COI) POLICY THROUGH TWO COMMITTEES: THE INDIVIDUAL COI COMMITTEE AND THE INSTITUTIONAL COI COMMITTEE. THE COI POLICY SERVES AS GUIDE FOR ALL STAFF MEMBERS OF THE ORGANIZATION. THE POLICY IS INTENDED TO 1) PROVIDE STAFF WITH A USEFUL RESOURCE WHEN DEVELOPING ACTIVITIES WITH OUTSIDE INDUSTRY AND 2) PROVIDE ASSURANCE TO STAFF THAT THERE IS A COMMITTEE TO REVIEW AND RESOLVE POTENTIAL CONFLICTS OF INTEREST IF / WHEN THEY ARISE. THE INDIVIDUAL COI COMMITTEE, CHAIRED BY THE DIRECTOR OF COMPLIANCE, GENERATES AN ANNUAL DISCLOSURE QUESTIONNAIRE DISTRIBUTED TO ALL STAFF TO ENFORCE THE POLICY. THE CONFLICTS COMMITTEE IS RESPONSIBLE FOR MAKING RECOMMENDATIONS TO THE DIRECTOR. RESOLUTIONS ARE IMPLEMENTED WITH APPROVAL OF THE COMMITTEE AND IN DISCUSSION WITH THE VAI CHAIRMAN. THE COI POLICY ALSO SERVES AS A GUIDE FOR ALL MEMBERS OF THE BOARD OF TRUSTEES AND SENIOR EXECUTIVES. THE INSTITUTIONAL COI COMMITTEE REQUIRES TRUSTEES TO COMPLETE AN ANNUAL DISCLOSURE STATEMENT. THIS STATEMENT AFFIRMS THEIR UNDERSTANDING OF THE POLICY, REQUIRES THEIR ACKNOWLEDGEMENT OF THE ORGANIZATION'S NONPROFIT STATUS, AND REQUESTS DISCLOSURE IF / WHEN POTENTIAL CONFLICTS ARISE. IN THE EVENT A POTENTIAL CONFLICT ARISES AT THE BOARD OR SENIOR OFFICER LEVEL, THE OFFICE OF THE GENERAL COUNSEL REVIEWS AND MEETS WITH THE BOARD OF TRUSTEES TO RESOLVE POTENTIAL CONFLICTS. | |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPENSATION FOR THE CEO, EXECUTIVE MANAGEMENT OFFICIALS, EXECUTIVE DIRECTOR, OFFICERS, AND KEY EMPLOYEES IS REVIEWED AND APPROVED ANNUALLY BY THE VAN ANDEL INSTITUTE'S INDEPENDENT COMPENSATION COMMITTEE. RECORDS AND DOCUMENTATION, INCLUDING COMPARABILITY DATA, ARE KEPT AND SUPPORT DECISIONS MADE ON BEHALF OF THESE ARRANGEMENTS AND ARE CONTEMPORANEOUSLY DOCUMENTED. | |
| FORM 990, PART VI, SECTION C, LINE 19 | THESE DOCUMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. | |
| FORM 990, PART VII, SECTION B | COMPENSATION FOR HUNT - OWEN AMES & KIMBALL EXCLUDES ESTIMATED MATERIALS AND INCLUDES ESTIMATED LABOR ON HUNT MANAGED SUB-CONTRACTORS. | |
| FORM 990, PART VII, SECTION B | JEFFREY BATTERSHALL IS LISTED AS SECRETARY ON PAGE 7. HE SERVED ON AN INTERIM BASIS AND WAS CONTRACTED FOR THIS PURPOSE THROUGH THE LAW FIRM WARNER, NORCROSS, & JUDD THROUGH OCTOBER 2011. ALL PAYMENTS FOR HIS SERVICES WERE PAID DIRECTLY TO WARNER, NORCROSS, & JUDD. | |
| FORM 990, PART VII, PAGE 7 | DAVID VAN ANDEL, R. JACK FRICK, TIMOTHY MYERS, JEFFREY BATTERSHALL, AND DAVID WHITESCARVER ALSO PERFORMED WORK FOR VAN ANDEL INSTITUTE, VAN ANDEL EDUCATION INSTITUTE, AND VAN ANDEL INSTITUTE GRADUATE SCHOOL (RELATED ENTITIES). | |
| CHANGES IN NET ASSETS OR FUND BALANCES: | FORM 990, PART XI, LINE 5: | NET UNREALIZED LOSSES ON INVESTMENTS: -251,644. LOSS ON BOND INTEREST SWAP -26,887,187. TOTAL TO FORM 990, PART XI, LINE 5: -27,138,831. |
| FORM 990, PART XII, LINE 2C | THE PROCESS FOR SELECTING THE AUDITOR FOR VAN ANDEL RESEARCH INSTITUTE'S FINANCIAL STATEMENTS DID NOT CHANGE DURING 2011. | |
| VARI'S THREE LARGEST PROGRAM SERVICES BY EXPENSES | FORM 990, PART III, LINES 4A-4C | LINE 4A - PROGRAM SERVICE ACTIVITY #1 THE LABORATORY OF STRUCTURAL SCIENCES IS FOCUSED ON STUDYING THE STRUCTURES AND FUNCTIONS OF PROTEIN/ LIGAND COMPLEXES THAT PLAY KEY ROLES IN MAJOR HORMONE SIGNALING PATHWAYS. THE LABORATORY ALSO WORKS ON EXPLORING THE STRUCTURAL INFORMATION TO DEVELOP THERAPEUTIC AGENTS FOR TREATING HUMAN DISEASE, INCLUDING CANCER AND DIABETES. LAB STUDIES USE MULTIDISCIPLINARY APPROACHES, INCLUDING MOLECULAR AND CELLULAR BIOLOGY, BIOCHEMISTRY, ANIMAL PHYSIOLOGY, X-RAY CRYSTALLOGRAPHY, AND PLANT HORMONE ABSCISIC ACID (ABA) RECEPTORS. RESEARCH IN THIS GROUP CURRENTLY FOCUSES ON THREE AREAS: NUCLEAR HORMONE RECEPTORS, THE MET TYROSINE KINASE RECEPTOR, AND G PROTEIN-COUPLED RECEPTORS. THESE PROTEINS, BEYOND THEIR FUNDAMENTAL ROLES IN BIOLOGY, ARE IMPORTANT DRUG TARGETS. RECENT DISCOVERIES INCLUDE: THE CRYSTAL STRUCTURES OF EACH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) LIGAND-BINDING DOMAIN (LBD) BOUND TO MANY DIVERSE LIGANDS IN ORDER TO UNDERSTAND THE MOLECULAR BASIS OF LIGAND-MEDIATED SIGNALING BY PPAR'S; THE CRYSTAL STRUCTURES OF THE RECEPTORS BOUND TO COACTIVATORS OR CO-REPRESSORS, WHICH PROVIDES A FRAMEWORK FOR UNDERSTANDING THE MECHANISMS OF PPAR AGONISTS AND ANTAGONIST AND THE RECRUITMENT OF COACTIVATORS AND CO-REPRESSORS; ANDROGEN RECEPTOR (AR) MUTATION IN PROSTATE CANCERS OFTEN RESULTS IN ENHANCED BINDING TO A PARTICULAR COACTIVATOR, SRC-3 (WHICH IS ALSO CALLED "AMPLIFIED IN BREAST CANCER1", OR AIB1); AND RETINOIC ACID IS A LOW-AFFINITY LIGAND FOR COUP-TF, WHICH IS ONE OF THE MOST CONSERVED NUCLEAR RECEPTORS AND HAS ESSENTIAL ROLES IN ANGIOGENESIS, HEART DEVELOPMENT, CNS ACTIVITY, AND METABOLIC HOMEOSTASIS. LINE 4B - PROGRAM SERVICE ACTIVITY #2 SINCE DISCOVERING THE C-MET RECEPTOR AND ITS LIGAND HEPATOCYTE GROWTH FACTOR (HGF/SF) IN THE MID-1980S, THE LABORATORY OF MOLECULAR ONCOLOGY HAS FOCUSED ON INVESTIGATING THE PARAMOUNT ROLE THESE PROTEINS PLAY IN MALIGNANT PROGRESSION AND METASTASIS. MET IS OVEREXPRESSED IN MANY TYPES OF HUMAN CANCER, AND ITS EXPRESSION CORRELATES WITH AN AGGRESSIVE DISEASE AND POOR PROGNOSIS (HTTP://WWW.VAI.ORG/MET/). THE MAJOR ADVANCES MADE IN THE PAST DECADE IN UNDERSTANDING HGF/SF-MET CELLULAR SIGNALING HAVE PROVIDED POWERFUL RATIONALE FOR THE DEVELOPMENT OF INHIBITORS TARGETING IT. SEVERAL OF THESE INNOVATIVE INHIBITORS ARE CURRENTLY BEING EVALUATED IN CLINICAL TRIALS (HTTP://WWW.VAI.ORG/METCLINICALTRIALS/). THE ABERRANT EXPRESSION OF MET IN MANY HUMAN TUMORS ALSO NECESSITATED THE DEVELOPMENT OF COMPANION DIAGNOSTICS TO IDENTIFY THOSE PATIENTS WHO COULD BENEFIT FROM MET TARGETED THERAPIES. IN COLLABORATION WITH DR. BRIAN CAO, WE HAVE DEVELOPED A MONOCLONAL ANTIBODY (DESIGNATED MET4), WHICH WE BELIEVE WILL PROVE VALUABLE AS A DIAGNOSTIC REAGENT AS WELL AS AN ESSENTIAL RESEARCH TOOL. AS PART OF THE ONGOING EFFORT TO FURTHER ENHANCE OUR UNDERSTATING OF THE HGF/SF-MET SIGNALING SYSTEM, OUR LAB CURRENTLY FOCUSES ON THE PROJECTS DESCRIBED BELOW: -CONTINUING TO DEVELOP AND CHARACTERIZE NOVEL RESEARCH MODELS FOR A VARIETY OF HUMAN CANCERS (LIVER, BRAIN, BREAST, LUNG AND OTHERS) AND USING THEM IN PRE-CLINICAL EVALUATION OF NEW C-MET INHIBITORS AS WELL AS OTHER THERAPEUTIC STRATEGIES -EVALUATING HGF AUTOCRINE AS A THERAPEUTIC MARKER PREDICTING SENSITIVITY TO C-MET INHIBITION USING VARIOUS GLIOBLASTOMA AND HEPATOCELLULAR CARCINOMA MODELS -INVESTIGATING THE UNIQUE ROLES THAT C-MET AND ERBB2 PLAY IN THE PROGRESSION AND METASTASIS OF AGGRESSIVE BREAST CANCERS -STUDYING THE MECHANISMS RESPONSIBLE FOR PHENOTYPIC SWITCHING (E-MT/M-ET) AND EVALUATING THE ROLE OF CHROMOSOME INSTABILITY IN TUMOR PROGRESSION -DETERMINING THE TUMOR SUPPRESSOR ROLE OF MIG-6 AS WELL AS INVESTIGATING THE MOLECULAR MECHANISM UNDERLYING ITS FUNCTION IN BOTH CANCER AND OSTEOARTHRITIS LINE 4C - PROGRAM SERVICE ACTIVITY #3 THE LABORATORY OF TRANSLATIONAL MEDICINE (LTM) IS FOCUSED ON TWO CRITICAL AREAS OF CANCER RESEARCH. AT THE BASIC SCIENCE LEVEL, THE LAB IS UTILIZING A RANGE OF MOLECULAR AND COMPUTATIONAL TECHNOLOGIES TO STUDY HOW TUMORS SPREAD TO DISTANT PARTS OF THE BODY FROM ITS ORIGINAL LOCATION - THIS PROCESS, KNOWN AS METASTASIS, IS ACCOUNTABLE FOR >90% OF CANCER RELATED DEATHS, AND THE IDENTIFICATION OF NEW DIAGNOSTIC AND TREATMENT STRATEGIES TARGETING THIS LETHAL PHENOTYPE OF CANCER ARE OF UTTERMOST IMPORTANCE. IN THE AREA OF APPLIED RESEARCH, THE LTM IS FOCUSED ON DEVELOPING AND IMPLEMENTING STRATEGIES TO "PERSONALIZE" THE TREATMENT OF A RANGE OF AGGRESSIVE CANCERS WITH MOLECULARLY-GUIDED THERAPIES. THE LTM CONTINUES TO BE AT THE FOREFRONT OF DESIGNING AND IMPLEMENTING APPROACHES IN WHICH THE TREATMENT OF AN INDIVIDUAL PATIENT'S CANCER IS BASED UPON THE MOLECULAR ANALYSIS OF THAT PATIENT AND THEIR SPECIFIC DISEASE. TO FACILITATE THIS, THE LAB DESIGNED AND DEVELOPED AN INTEGRATED, BIOMEDICAL INFORMATICS SYSTEM FOR DATA MANAGEMENT, ANALYSIS, AND REPORTING (KNOWN AS XENOBASE BIOINTEGRATION SUITE (XB-BIS)). IN ADDITION, THE LAB HAS BEEN HEAVILY INVOLVED IN COMMUNITY FOUNDING PARTNERSHIPS THAT HAVE INCLUDED THE FORMATION OF A BIOMARKER-DRIVEN CLINICAL TRIALS CONSORTIUM (CLINXUS), A HIGH COMPLEXITY CLIA CERTIFIED LABORATORY (THE CENTER FOR MOLECULAR MEDICINE), AND A PERSONALIZED MEDICINE INFORMATION SERVICE COMPANY (INTERVENTION INSIGHTS) WHICH COLLECTIVELY, PERMIT THE APPLICATION OF PERSONALIZED THERAPY FOR LATE STAGE CANCER PATIENTS. RECENT ACCOMPLISHMENTS INCLUDE THE DEVELOPMENT AND COMMERCIALIZATION OF AN INTEGRATED INFORMATICS SOLUTION (XB-BIS), WHICH ENABLES EFFICIENT EXCHANGE OF INFORMATION BETWEEN THE BASIC RESEARCH LABORATORY AND THE CLINIC FOR EFFECTIVE TRANSLATIONAL RESEARCH. XB-BIS HAS BEEN LICENSED TO TRANSMED SYSTEMS WHICH IS NOW SUPPORTING ITS ADOPTION ACROSS MULTIPLE GROUPS ENGAGED IN TRANSLATIONAL RESEARCH BOTH WITHIN THE UNITED STATES AND BEYOND. IN PART THROUGH THE USE OF XB-BIS, THE LAB RECENTLY COMPLETED A FEASIBILITY STUDY OF 50 LATE-STAGE PEDIATRIC AND ADULT CANCER PATIENTS IN WHICH TUMOR-DERIVED GENE EXPRESSION PROFILES WERE ANALYZED TO IDENTIFY POTENTIAL DRUGS TO TARGET PERTURBED MOLECULAR COMPONENTS OF EACH PATIENT'S SPECIFIC TUMOR. ANECDOTAL SIGNS OF SUCCESS IN A HANDFUL OF PATIENTS PROVIDED THE IMPETUS TO LAUNCH A SERIES OF FOLLOW-UP STUDIES WITHIN FOCUSED PATIENT POPULATIONS, AND ALSO LED TO THE FORMATION OF INTERVENTION INSIGHTS, A PERSONALIZED MEDICINE INFORMATION SERVICE THAT SUPPORTS COMMUNITY AND ACADEMIC ONCOLOGISTS ACROSS THE UNITED STATES. AT VARI, THE LTM CONTINUES TO ADVANCE THE MOLECULAR AND COMPUTATIONAL TECHNOLOGIES AND IS CURRENTLY INVESTIGATING THE POTENTIAL USE OF NEXT GENERATION SEQUENCING TECHNOLOGIES IN TARGETED TRIALS OF NEUROBLASTOMA (SPONSORED BY THE NEUROBLASTOMA AND MEDULLOBLASTOMA TRANSLATIONAL RESEARCH CONSORTIUM (NMTRC) AND IN PARTNERSHIP WITH DELL AND INTERVENTION INSIGHTS), METASTATIC MELANOMA (SPONSORED BY A RECENT STAND UP 2 CANCER GRANT), TRIPLE NEGATIVE BREAST CANCER (SPONSORED BY A KOMEN PROMISE GRANT), AND GLIOBLASTOMA (SPONSORED BY HENRY FORD HOSPITAL AND A RECENT NIH GRANT). |
| FORM 990, PART III, LINE 4D | ALL OTHER PROGRAM SERVICE ACTIVITIES IN 2011, VARI RESEARCHERS FOUND WAYS TO POTENTIALLY DIAGNOSE AND FIGHT SEVERAL DIFFERENT TYPES OF CANCER. IN 2011, VARI ALSO ANNOUNCED A PATENT WITH GENTEL BIOSCIENCES, A LEADER IN PROTEOMICS TOOLS, FOR A NEW APPROACH TO IDENTIFY BIOLOGICAL MARKERS TO HELP DIAGNOSE DISEASES SUCH AS CANCER. BELOW ARE OTHER EXAMPLES OF SIGNIFICANT RESEARCH FINDINGS: -VARI ANNOUNCED THE CREATION OF THE VARI PEDIATRIC CANCER TRANSLATIONAL RESEARCH PROGRAM, A PROJECT THAT UNITES BASIC RESEARCH AND CLINICAL CARE THROUGH A NATIONWIDE CONSORTIUM OF PARTNERS. -RESEARCHERS DETERMINED HOW THE ANTI-CANCER ANTIBIOTIC GELDANAMYCIN AND ITS DERIVATIVE 17AAG WORK IN MORE DETAIL AND HAVE UNCOVERED A POSSIBLE EXPLANATION FOR SIDE EFFECTS, WHICH COULD INFORM FUTURE DRUG DESIGN. -RESEARCHERS IDENTIFIED MK-STYX AS AN ENZYME THAT HELPS TO REGULATE CELL DEATH, AND FOUND OUT MORE ABOUT SPECIFICALLY HOW MK-STYX WORKS. -RESEARCHERS IDENTIFIED THE GENE POLO-LIKE KINASE 1 (PLK1) AS A NEW POTENTIAL DRUG TARGET TO TREAT CLEAR CELL RENAL CELL CARCINOMA (CCRCC), THE MOST COMMON FORM OF KIDNEY CANCER. THEY ALSO FOUND THAT THE PLK1 INHIBITOR BI 2536, CURRENTLY IN CLINICAL TRIALS FOR THE TREATMENT OF SEVERAL CANCERS, LED TO DRAMATIC REGRESSION OF CCRCC TUMORS. -RESEARCHERS IDENTIFIED AN ENZYME, LRRK2, THAT SEEMS TO COOPERATE WITH MET, AN IMPORTANT GENE IN SEVERAL CANCERS, TO PROMOTE TUMOR CELL GROWTH AND SURVIVAL, SPECIFICALLY IN PAPILLARY RENAL AND THYROID CARCINOMAS. -RESEARCHERS IDENTIFIED SPECIFIC PROTEINS THAT CARRY THE CA 19-9, THE BEST INDICATOR OF PANCREATIC CANCER, ANTIGEN AND MEASURED CA 19-9 LEVELS ON EACH PROTEIN IN AN EFFORT TO ENHANCE BLOOD TESTING. BETTER KNOWLEDGE OF THESE CARRIERS IN VARIOUS DISEASE STATES COULD LEAD TO IMPROVED DIAGNOSTIC TESTS. -RESEARCHERS INVESTIGATED THE ROLE OF THE PROTEIN HEPATOMA-DERIVED GROWTH FACTOR (HDGF) IN BREAST AND PROSTATE CANCERS AND FOUND THAT IT MAY PROMOTE CELL GROWTH IN THESE CANCERS AND COULD BE A THERAPEUTIC TARGET. -RESEARCHERS FOUND THAT IN SK-MEL-28 MELANOMA CELLS, MEK2, AND NOT MEK1, IS SUFFICIENT FOR CELL PROLIFERATION, BUT THAT MEK1 CAN COMPENSATE FOR THE LOSS OF MEK2 ACTIVITY. THESE INSIGHTS MAY AID IN THE DESIGN OF MORE EFFECTIVE THERAPIES FOR TREATING MELANOMA AND OTHER MEK-DEPENDENT CANCERS. -IN COLLABORATION WITH RESEARCHERS FROM ANOTHER ORGANIZATION, RESEARCHERS IDENTIFIED A NOVEL MARKER THAT COULD HELP DIAGNOSE TYPE II EATL, WHICH IS THE TYPE MORE COMMON IN ASIA AND NOT ASSOCIATED WITH COELIAC DISEASE. -IN ADDITION TO THOSE LISTED ABOVE, THERE WERE ALSO FINDINGS WITHIN MELANOMA, BRAIN CANCER, HEAD AND NECK CANCER, ALZHEIMER'S DIABETES, AUTOIMMUNE DISEASE, RETINOPATHY, AND HOOKWORM. | |
| FORM 990, PART X, LINE 33 | VARI NET ASSETS SHOULD BE CONSIDERED ON A CONSOLIDATED BASIS WITH VAN ANDEL INSTITUTE (VAI), VAN ANDEL EDUCATION INSTITUTE (VAEI), AND THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), RELATED PARTIES. ON A CONSOLIDATED BASIS, NET ASSETS ARE $896,445,000 PER AUDITED FINANCIAL STATEMENTS. THE NEGATIVE NET ASSETS AT VARI ARE DUE TO VAI FUNDING EXPENSES ON A CASH BASIS AND GUARANTEEING VARI'S LONG-TERM DEBT AND UNREALIZED BOND SWAP LOSS. | |
| FORM 990, PART IX, COLUMN D | FUNDRAISING EXPENSES AT VARI WERE INCURRED TO SUPPORT THE MISSION OF THE RESEARCH INSTITUTE THROUGH GRANT SOLICITATION AND EXTRAMURAL PROPOSAL PREPARATION. | |
| FORM 990, PART VI, LINES 12-14 | THE INSTITUTE DOES HAVE A WRITTEN CONFLICT OF INTEREST POLICY, A WRITTEN WHISTLEBLOWER POLICY, AND A WRITTEN DOCUMENT RETENTION POLICY; HOWEVER, IS REQUIRED TO CHECK NO BASED ON THE IRS INSTRUCTIONS AS THESE POLICIES HAVE NOT BEEN OFFICIALLY APPROVED BY OUR BOARD. |
| Software ID: | |
| Software Version: |